Fully Integrated Technology for rapid and multiplex Bacterial Identification
Invasive neonatal infections constitute a significant global public health challenge claiming 6 deaths per 1000 births. The perinatal period is a critical time for invasive neonatal infections. Among these infections, neonatal bac...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
OUTSMART-infection
Microbiome centered prediction and prevention of recurrent i...
3M€
Cerrado
ResisCHIP
Rapid chip-based detection of antibiotic resistances
150K€
Cerrado
CPP2021-008459
AmpliSens. Pruebas rápidas de características mejoradas para...
180K€
Cerrado
BIO2014-54507-R
ESTANDARIZACION DE METODOS PREDICTIVOS DE ANALISIS DE LA RES...
278K€
Cerrado
SNIP-AFRICA
Severe neonatal infection adaptive platform trials in Africa
7M€
Cerrado
PID2021-124867OB-I00
PROXIMA GENERACION DE DIAGNOSTICOS PARA COMBATIR LA RESISTEN...
214K€
Cerrado
Información proyecto FIT-BI
Duración del proyecto: 30 meses
Fecha Inicio: 2022-12-02
Fecha Fin: 2025-06-11
Líder del proyecto
BFORCURE
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
212K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Invasive neonatal infections constitute a significant global public health challenge claiming 6 deaths per 1000 births. The perinatal period is a critical time for invasive neonatal infections. Among these infections, neonatal bacterial infections primarily acquired at the time of delivery through maternal-fetal transmission, remain a leading preventable cause of mortality and morbidity. This public health concern is further exacerbated by the emergence and escalation of antimicrobial resistance (AMR) which is jeopardizing essential benefits made since the discovery of antibiotics especially, the contribution of these drugs to improvements in maternal, neonatal and child mortality. Despite the advancements made in the reduction of morbidity and mortality from neonatal infections, diagnostics still relies primarily on conventional microbiology techniques which are time-consuming and can be inaccurate. Diagnostics with a faster turnaround time would likely improve surveillance in all settings but also enable timely management of infections. FIT-BI is timely as it will enable the development of rapid diagnostic kits allowing real-time bacterial identification and prediction of antimicrobial susceptibility patterns, curbing thereby extensive antibiotic use and AMR; and contributing to the achievement of the sustainable development goals 1 and 3 in an advanced and sustainable manner. This promising undertaking will greatly expand the ER's scientific expertise in multi-disciplinary and state-of-the-art fields including Molecular Biology, Microfluidics and Flow Chemistry, impacting her future career, and positioning her as a leading independent researcher bridging the world of academia and industry. Furthermore, the proposed application has great public potential, as it will contribute to tailoring antibiotic therapy, and improving patient management and prognosis while de-escalating AMR in Europe and beyond.